Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News AC Immune SA ACIU

Healthcare Biotechnology
AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small... see more

Recent & Breaking News (NDAQ:ACIU)

AC Immune Reports Changes to Senior Management

GlobeNewswire April 8, 2022

AC Immune KOL Webinar on First Clinical Proof of Concept for Alpha-synuclein Diagnostic Shows Breakthrough Potential for Neurodegenerative diseases

GlobeNewswire March 30, 2022

AC Immune Reports Full Year 2021 Financial Results and Provides Corporate Update

GlobeNewswire March 22, 2022

AC Immune to Host Key Opinion Leader Webinar on Alpha-Synuclein as a Target in Neurodegenerative Diseases

GlobeNewswire March 21, 2022

AC Immune Reports First Live Images of Alpha-Synuclein in Human Brain with New PET Tracer for Neurodegenerative Disease at AD/PDTM Conference

GlobeNewswire March 16, 2022

AC Immune to Present at the AD/PD(TM) 2022 New Clinical and Preclinical Data for Alpha-Synuclein, Abeta and TDP-43 Programs

GlobeNewswire February 28, 2022

AC Immune ACI-35.030 Phase 1b/2a Trial Interim Data Confirm Consistent Safety and Potent Immunogenicity of pTau Alzheimer's Vaccine in High-dose Cohort

GlobeNewswire February 15, 2022

AC Immune ACI-24 Data in Brain Communications Show Abeta Vaccine-Candidate Induces Immunity Against pyroGlu-Abeta, Key Driver of Alzheimer's Disease

GlobeNewswire February 4, 2022

AC Immune to Present at the SVB Leerink 11th Annual Global Healthcare Conference

GlobeNewswire February 2, 2022

AC Immune Awarded Two Michael J. Fox Foundation Grants to Advance Small Molecule Parkinson's Disease Programs

GlobeNewswire December 15, 2021

AC Immune Announces Interim Phase 1b/2a Data Showing that its ACI-35.030 Anti-pTau Alzheimer's Vaccine Generates a Potent Immune Response

GlobeNewswire November 12, 2021

AC Immune Announces Late-Breaker Presentation by Genentech at CTAD on Phase 2 Lauriet Study of Semorinemab in Mild-to-Moderate Alzheimer's Disease

GlobeNewswire November 10, 2021

AC Immune Reports Third Quarter 2021 Financial Results and Provides Corporate Update

GlobeNewswire November 8, 2021

AC Immune Extends Research Collaboration with University of Pennsylvania Focusing on the Pathogenic Protein TDP-43, a Major Driver of Neurodegenerative Diseases

GlobeNewswire November 4, 2021

New Data on AC Immune's Abeta and pTau Clinical Programs in Alzheimer's Disease To Be Presented at CTAD 2021

GlobeNewswire November 2, 2021

AC Immune Holds its Extraordinary General Meeting and Appoints Monica Shaw, M.D., and Prof. Monika Bütler, Dr. oec., to its Board of Directors

GlobeNewswire October 29, 2021

AC Immune to Present at the Jefferies London Healthcare Conference

GlobeNewswire October 25, 2021

AC Immune CEO Andrea Pfeifer Receives First SEF.WomenAward for CEO of the Year

GlobeNewswire September 3, 2021

AC Immune to Participate in Upcoming Virtual Investor Conferences in September

GlobeNewswire September 2, 2021

AC Immune Announces First Positive Cognitive Results for a Tau-Targeting Monoclonal Antibody in Alzheimer's Disease

GlobeNewswire August 31, 2021